IPO
ADEL Inc.
아델
What the company does
ADEL is a biotech company spun off from Asan Medical Center in 2016 that develops drugs for Alzheimer's disease and other degenerative brain diseases. It develops antibody therapies that target disease-specific forms of proteins and licenses candidates to global pharmaceutical companies.
Themes:Biotech (new drugs)
- Market
- KOSDAQ
- Price range
- Not set yet
- Offer price
- ₩18,000
- Subscription
- Nov 23 – Nov 24
- Payment date
- Nov 26, 2026
- Listing
- Not set yet
- Shares offered
- 2,170,000
- Raising
- ₩39.1B
Lead managers: Samsung Securities, Mirae Asset Securities
Filings
- [기재정정]증권신고서(지분증권)Oct 27, 2026Open on DART ↗
- 증권신고서(지분증권)Oct 12, 2026Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 27, 2026 · IPO calendar